Merck & Co Archives -

Merck & Co’s earlier efforts to find new therapies for Alzheimer’s disease resulted in failure, but the company

Merck swings back into Alzheimer’s with $1.1bn Cerevance alliance

https://pharmaphorum.com/news/merck-swings-back-into-alzheimers-with-1-1bn-cerevance-alliance/

Radiology technician examens mammography test

News/ News/ News/ Oncology/ Sales and Marketing

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy

Phil Taylor adjuvant, AstraZeneca, breast cancer, EU, Lynparza, Merck & Co, Oncology, targeted oncology 0 Comment

The European Commission has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant treatment for breast cancer,

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy

https://pharmaphorum.com/news/az-merck-get-eu-nod-for-lynparza-as-adjuvant-breast-cancer-therapy/

News/ News/ News/ Oncology/ R&D

Keytruda fluffs its lines in prostate, liver cancer trials

Phil Taylor immuno-oncology, Keytruda, Liver cancer, Merck & Co, Oncology, Prostate cancer 0 Comment

Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver

Keytruda fluffs its lines in prostate, liver cancer trials

https://pharmaphorum.com/news/keytruda-fluffs-its-lines-in-prostate-liver-cancer-trials/

News/ News/ News/ Oncology/ Sales and Marketing

Merck sees big lift in Keytruda sales, as Senate probes its taxes

Phil Taylor Financial, Gardasil, Keytruda, Lagevrio, Merck & Co, tax, US 0 Comment

Merck & Co has reported record sales of its cancer immunotherapy Keytruda in the second quarter, as members

Merck sees big lift in Keytruda sales, as Senate probes its taxes

https://pharmaphorum.com/news/merck-sees-big-lift-in-keytruda-sales-as-senate-probes-its-taxes/

News/ News/ R&D

NewAmsterdam goes public to advance drug in abandoned class

Phil Taylor cardiovascular, cholesterol, Merck & Co, NewAmsterdam Pharma, obicetrapib, R&D 0 Comment

NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier

NewAmsterdam goes public to advance drug in abandoned class

https://pharmaphorum.com/news/newamsterdam-goes-public-to-advance-drug-in-abandoned-class/

Digital/ News/ News

After cough drug setback, Merck partners Hyfe’s tracking app

Phil Taylor cough, digital, digital health, gefapixant, Hyfe, Merck & Co, partnering, Pfizer, ResApp Health 0 Comment

Merck & Co has signed a deal with digital health firm Hyfe that will see its cough-detecting smartphone

After cough drug setback, Merck partners Hyfe’s tracking app

https://pharmaphorum.com/news/after-cough-drug-setback-merck-partners-hyfes-tracking-app/

News/ News/ News/ Oncology/ R&D

Bid to expand Keytruda use in head and neck cancer therapy fails

Phil Taylor head and neck cancer, immuno-oncology, Keytruda, Merck & Co, Oncology 0 Comment

While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact

Bid to expand Keytruda use in head and neck cancer therapy fails

https://pharmaphorum.com/news/bid-to-expand-keytruda-use-in-head-and-neck-cancer-therapy-fails/

News/ News/ News/ Oncology/ R&D

Disappointment as Lynparza fails colorectal cancer test

Phil Taylor AstraZeneca, colorectal cancer, Lynparza, Merck & Co, Oncology, PARP inhibitor 0 Comment

AstraZeneca and Merck’s PARP inhibitor Lynparza has carved out blockbuster revenues across uses in breast, ovarian, prostate and

Disappointment as Lynparza fails colorectal cancer test

https://pharmaphorum.com/news/disappointment-as-lynparza-fails-colorectal-cancer-test/

News/ News/ News/ Oncology/ R&D

Merck buys into Orion prostate cancer therapy in $290m deal

Phil Taylor Merck & Co, Oncology, Orion, partnering, Prostate cancer 0 Comment

Merck & Co has added another clinical-stage drug to its oncology pipeline via a licensing agreement with Finland’s

Merck buys into Orion prostate cancer therapy in $290m deal

https://pharmaphorum.com/news/merck-buys-into-orion-prostate-cancer-therapy-in-290m-deal/

Trending

Merck & Co

Login